Quanterix Corporation · NASDAQ:QTRX

Quanterix — Technical Presentation (October 2015)

20 slides from Quanterix's technical presentation, Oct 29, 2015

  1. Slide 1: A Cytokine Assay Challenge: Sensitivity and Specificity

    Slide 1: A Cytokine Assay Challenge: Sensitivity and Specificity

    A Cytokine Assay Challenge: Sensitivity and Specificity Jane Ruppel, Genentech Proteins Powering NextGen Healthcare 29 October 2015

  2. Slide 2: Outline

    Slide 2: Outline

    Outline  Background:  Purpose of study  Analyte  Key factors in assay development  Assay characterization  Summary 2 2

  3. Slide 3: IL-17FF Assay Done as Feasibility Project

    Slide 3: IL-17FF Assay Done as Feasibility Project

    IL-17FF Assay Done as Feasibility Project  Objective: to develop a sensitive and specific assay on the Simoa platform  Key features:  Sensitivity  Spike recovery  Linearity of dilution  Specificity  IL-17FF antibody pair already characterized, had good performance features  Antibody pair did

  4. Slide 4: IL-17FF Background

    Slide 4: IL-17FF Background

    IL-17FF Background  T helper 17 (Th17) cells are implicated in autoinflammatory diseases  Inflammatory bowel disease, asthma, rheumatoid arthritis, systemic lupus erythematosis  Th17 cytokines may be indicators of disease state and drug response  IL-17 (AA, A/F, FF), IL-22, IL-26  IL-17A and IL

  5. Slide 5: Assay Development Starting Point

    Slide 5: Assay Development Starting Point

    Assay Development Starting Point  Development focused on achieving high sensitivity  Reducing background while increasing signal response to analyte  Few samples expected with concentrations > 1 pg/mL  Larger assay dynamic range was achievable, but we opted for a lower range standard curve Tools

  6. Slide 6: Diluent and Reagents Optimized for Sensitivity

    Slide 6: Diluent and Reagents Optimized for Sensitivity

    Diluent and Reagents Optimized for Sensitivity  Low and high salt concentration Buffer Ionic strength  Triton X-100, CHAPS and Tween 20  HEPES and PBS Diluent Protein Surfactant  Varying pH  BSA and FBS  IIR blocker and mouse IgG Blockers pH Modulate concentrations of capture and detection ant

  7. Slide 7: Final IL17FF Assay Configuration

    Slide 7: Final IL17FF Assay Configuration

    Final IL17FF Assay Configuration Capture antibody Mouse monoclonal anti-IL17FF covalently coupled to beads at 0.3 mg/mL Detection antibody Mouse monoclonal anti-IL17FF-biotin Minimum sample dilution 1/4 Standard/sample diluent 50% FBS, 0.5% BSA, 0.05% Tween 20, 0.05% ProClin 300 + 0.5 mg/mL mouse Ig

  8. Slide 8: LLOQ of 0.02 pg/mL was Achieved Based on Variability of Standard

    Slide 8: LLOQ of 0.02 pg/mL was Achieved Based on Variability of Standard

    LLOQ of 0.02 pg/mL was Achieved Based on Variability of Standard Diluent signal + 2 SD < LLOQ – 2SD %CV of LLOQ < 20% 0.008 0.007 I L 1 7 F F C a l i b ra t o r ( p g / m L ) 0.006 0 0 .0 2 0 .0 3 9 0 .0 7 8 AEB ± 2 sd (n=12) 0.005 M e an sig n al 0.00246 0.00639 0.00990 0.01623 0.004 S ig n a l s t

  9. Slide 9: Approaches for Spike Recovery

    Slide 9: Approaches for Spike Recovery

    Approaches for Spike Recovery  For PK assays, lowest spike concentration that shows acceptable recovery and precision is used for determining LLOQ  Approach not as straightforward for biomarkers due to presence of endogenous analyte  Use spike plus measured endogenous concentration for 100% targe

  10. Slide 10: Spike Recovery Was Acceptable

    Slide 10: Spike Recovery Was Acceptable

    Spike Recovery Was Acceptable 6 of 6 low spikes recovered well (70% to 130%) 4 of 5 high spikes recovered well Sample [IL-17FF] % Recovery (pg/mL) + 0.25 + 1.25 + 2.5 pg/mL pg/mL pg/mL 1 0.155 120% 102% - 2 0.149 77% 65% - 3 * 0.314 108% 99% - 4 0.347 103% - 126% 5 2.02 104% - GTR 6 < 0.08 94% - 8

  11. Slide 11: Linearity of Dilution of Endogenous Human Serum Samples was Acceptable

    Slide 11: Linearity of Dilution of Endogenous Human Serum Samples was Acceptable

    Linearity of Dilution of Endogenous Human Serum Samples was Acceptable  Demonstrates that endogenous protein and the recombinant standard Linearity of Endogenous Samples (Concentration) behave the same in the assay 3  Factors such as binding proteins, 2.5 interferences or analyte isoforms [IL17FF]

  12. Slide 12: Is the Measurement Specific?

    Slide 12: Is the Measurement Specific?

    Is the Measurement Specific?  Not all measured signals are analyte-specific  Interferences due to factors such as heterophilic antibodies  Increasing sample dilution can reduce some interferences  Nonspecific signals can dilute linearly  Added blockers may not eliminate all nonspecific signals

  13. Slide 13: Some Methods for Testing Specificity

    Slide 13: Some Methods for Testing Specificity

    Some Methods for Testing Specificity Orthogonal Depletion Competition Capture analyte on Absorb out analyte from Use capture antibody added antibody beads, analyze sample using solid phase to sample diluent to block using LC-MS/MS antibody before analysis analyte binding to beads Use isotype antibod

  14. Slide 14: Specificity Using Competition with Capture Antibody

    Slide 14: Specificity Using Competition with Capture Antibody

    Specificity Using Competition with Capture Antibody Each sample tested using three diluents: Standard assay diluent With soluble capture antibody With isotype control antibody - analyte binds to bead - bead binding blocked - analyte binds to bead 14 14

  15. Slide 15: Example of Specificity Issue in a Different Assay/Platform

    Slide 15: Example of Specificity Issue in a Different Assay/Platform

    Example of Specificity Issue in a Different Assay/Platform - Results are Nonspecific Positive control behaves as expected:  Gives signal when tested without competitor  Anti-analyte antibody reduces signal by blocking binding  Control antibody does not block binding Sample signal is nonspecific:

  16. Slide 16: IL17FF Assay Specificity Was Acceptable

    Slide 16: IL17FF Assay Specificity Was Acceptable

    IL17FF Assay Specificity Was Acceptable Anti-IL17FF competitive antibody reduced all sample signals below detection 2.5 Sample With 9076 With isotype No competition Competition with capture ab 2 Competition with control ab IL17FF Concentration (pg/mL) 1.5 1 0.5 0 0.08 pg/mL 1 2 3 4 5 6 7 8 9 10 11 1

  17. Slide 17: Summary

    Slide 17: Summary

    Summary  Feasibility shown for IL-17FF assay in human serum, with excellent sensitivity and specificity  Many of the lessons learned from standard immunoassays can be applied to ultrasensitive assays  Ultrasensitive assay platforms can both improve detectability of analytes but may also amplify a

  18. Slide 18: Acknowledgments

    Slide 18: Acknowledgments

    Acknowledgments Cecilia Leddy Jessica Li Cheryl Schofield Ann Brady Kristin Wallace Eric Wakshull 18 18

  19. Slide 19: Thank You

    Slide 19: Thank You

    THANK YOU Genentech ‘A Member of the Roche Group

  20. Slide 20: Doing now what patients need next

    Slide 20: Doing now what patients need next

    Doing now what patients need next 20

Source: Internet Archive copy of quanterix.com

More decks from Quanterix Corporation

All 47 Quanterix decks